Skip to content

Clinical trials

Phase 2 Hematologic Neoplasms trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Hematologic Neoplasms Phase: Phase 2 Country / region: United States Clear all

194 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20023
20032
20045
20052
20064
20076
20085
20097
20109
20117
201211
201310
201413
201516
201620
20177
20183
20193
202012
202111
20227
20236
20244
20257
20264

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed89
Terminated34
Active, not recruiting33
Recruiting22
Withdrawn13
Not yet recruiting3

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)30
M.D. Anderson Cancer Center25
Fred Hutchinson Cancer Center9
Novartis Pharmaceuticals8
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University7
Memorial Sloan Kettering Cancer Center5
St. Jude Children's Research Hospital5
Medical College of Wisconsin4
Stanford University4
Bristol-Myers Squibb3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Hematologic Neoplasms194
Multiple Myeloma48
Lymphoma45
Leukemia31
Leukemia, Myeloid, Acute31
Myelodysplastic Syndromes29
Lymphoma, Non-Hodgkin26
Precursor Cell Lymphoblastic Leukemia-Lymphoma26
Graft vs Host Disease23
Hodgkin Disease23

Trials

Showing 1 to 25 of 194. Each trial links to its page on Pharma Observatory.

94 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.